EUVIMEDEUVIMED entdecken
Systematische ÜbersichtNetzwerk-MetaanalyseOpen Access · CC BY-NC 4.0

Efficacy and Safety of Different Hybrid Closed Loop Systems for Automated Insulin Delivery in People With Type 1 Diabetes: A Systematic Review and Network Meta‐Analysis

Wirksamkeit und Sicherheit verschiedener Hybrid-Closed-Loop-Systeme zur automatisierten Insulinabgabe bei Menschen mit Typ-1-Diabetes: systematische Übersicht und Netzwerk-Metaanalyse

Sergio Di Molfetta iD, Ludovico Di Gioia iD, Irene Caruso iD, Angelo Cignarelli iD, Suetonia C Green iD, Patrizia Natale iD, Giovanni F M Strippoli iD, Gian Pio Sorice iD, Sebastio Perrini iD, Annalisa Natalicchio iD, Luigi Laviola iD, Francesco Giorgino iD

Diabetes/Metabolism Research and Reviews · 2024-09 · 40 (6)

DOI: 10.1002/dmrr.3842 ↗

Auf einen Blick

28 RCTs zeigen: HCL-Systeme erhöhten die Zeit im Zielbereich gegenüber subkutaner Insulintherapie ohne kontinuierliche Glukosemessung. Minimed 780G erreichte die höchste TIR.

Fragestellung

Wie wirksam und sicher sind verschiedene Hybrid-Closed-Loop-Systeme bei Menschen mit Diabetes im Vergleich zu anderen Insulintherapien?

Methode

Systematische Übersicht und Netzwerk-Metaanalyse randomisierter klinischer Studien; Suche in MEDLINE, EMBASE, CENTRAL und PubMed.

Ergebnisse

28 RCTs, alle mit Menschen mit Typ-1-Diabetes. Minimed 780G lag bei TIR vor Control-IQ (MD 5,1 %, 95 %-KI 0,68–9,52), Minimed 670G (MD 7,48 %, 95 %-KI 4,27–10,7), CamAPS Fx (MD 8,94 %, 95 %-KI 4,35–13,54) und DBLG1 (MD 10,69 %, 95 %-KI 5,73–15,65).

Schlussfolgerung der Autor:innen

Die Autor:innen berichten eine Wirksamkeitshierarchie zwischen den HCL-Systemen bei Menschen mit Typ-1-Diabetes und sehen dies als Unterstützung für klinische Entscheidungen.

Kernaussagen

  • HCL-Systeme erhöhten die Time in Range gegenüber SIT ohne CGM.
  • Minimed 780G erzielte die höchste TIR.
  • Schwere Hypoglykämie und DKA waren ähnlich häufig wie unter anderer Insulintherapie.

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Systematische Übersicht in der Zeitschrift Diabetes/Metabolism Research and Reviews, online erschienen am 19.09.2024. Verfasst von Sergio Di Molfetta und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Precision and Regenerative Medicine and Ionian Area, Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, Uni…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Hypoglycemic Agents, Insulin, Insulin Infusion Systems. Die Arbeit wurde bisher 84-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Next Generation EU, National Recovery and Resilience Plan, Investment PE8-Project Age-It: 'Ageing Well in an Ageing Society'.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To compare the efficacy and safety of different hybrid closed loop (HCL) systems in people with diabetes through a network meta‐analysis.

Methods

We searched MEDLINE, EMBASE, CENTRAL and PubMed for randomised clinical trials (RCTs) enrolling children, adolescents and/or adults with type 1 or type 2 diabetes, evaluating Minimed 670G, Minimed 780G, Control‐IQ, CamAPS Fx, DBLG‐1, DBLHU, and Omnipod 5 HCL systems against other types of insulin therapy, and reporting time in target range (TIR) as outcome.

Results

A total of 28 RCTs, all enrolling people with type 1 diabetes, were included. HCL systems significantly increased TIR compared with subcutaneous insulin therapy without continuous glucose monitoring (SIT). Minimed 780G achieved the highest TIR ahead of Control IQ (mean difference (MD) 5.1%, 95% confidence interval (95% CI) [0.68; 9.52], low certainty), Minimed 670G (MD 7.48%, 95% CI [4.27; 10.7], moderate certainty), CamAPS Fx (MD 8.94%, 95% CI [4.35; 13.54], low certainty), and DBLG1 (MD 10.69%, 95% CI [5.73; 15.65], low certainty). All HCL systems decreased time below target range, with DBLG1 (MD −3.69%, 95% CI [−5.2; −2.19], high certainty), Minimed 670G (MD −2.9%, 95% CI [−3.77; −2.04], moderate certainty) and Minimed 780G (MD −2.79%, 95% CI [−3.94; −1.64], high certainty) exhibiting the largest reductions compared to SIT. The risk of severe hypoglycaemia and diabetic ketoacidosis was similar to other types of insulin therapy.

Conclusions

We show a hierarchy of efficacy among the different HCL systems in people with type 1 diabetes, thus providing support to clinical decision‐making. Trial Registration: PROSPERO CRD42023453717

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1Hypoglycemic AgentsInsulinInsulin Infusion SystemsHumansBlood GlucosePrognosisRandomized Controlled Trials as TopicContinuous Glucose Monitoring

Stichwörter der Autor:innen

Time In Rangeautomated insulin deliveryhybrid closed looptype 1 diabetes

Substanzen

Blood GlucoseHypoglycemic AgentsInsulin

Autor:innen und Institutionen

  • Department of Precision and Regenerative Medicine and Ionian Area, Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, University of Bari Aldo Moro, Bari, Italy.
  • Department of Medicine, University of Otago Christchurch, Christchurch, New Zealand.
  • Department of Precision and Regenerative Medicine and Ionian Area, University of Bari Aldo Moro, Bari, Italy.
  • Sydney School of Public Health, The University of Sydney, Sydney, Australia.
  • Nephrology, Dialysis and Transplantation Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.

ORCID-Profile: Sergio Di Molfetta, Ludovico Di Gioia, Irene Caruso, Angelo Cignarelli, Suetonia C Green, Patrizia Natale, Giovanni F M Strippoli, Gian Pio Sorice, Sebastio Perrini, Annalisa Natalicchio, Luigi Laviola, Francesco Giorgino

Förderung

  • Next Generation EU, National Recovery and Resilience Plan, Investment PE8-Project Age-It: 'Ageing Well in an Ageing Society'

Zitieren

APA

Di Molfetta, S., Di Gioia, L., Caruso, I., Cignarelli, A., Green, S. C., Natale, P., Strippoli, G. F. M., Sorice, G. P., Perrini, S., Natalicchio, A., Laviola, L., & Giorgino, F. (2024). Efficacy and Safety of Different Hybrid Closed Loop Systems for Automated Insulin Delivery in People With Type 1 Diabetes: A Systematic Review and Network Meta‐Analysis. Diabetes/Metabolism Research and Reviews, 40(6). https://doi.org/10.1002/dmrr.3842

Vancouver

Di Molfetta S, Di Gioia L, Caruso I, Cignarelli A, Green SC, Natale P, et al. Efficacy and Safety of Different Hybrid Closed Loop Systems for Automated Insulin Delivery in People With Type 1 Diabetes: A Systematic Review and Network Meta‐Analysis. Diabetes/Metabolism Research and Reviews. 2024;40(6). doi:10.1002/dmrr.3842

BibTeX
@article{DiMolfetta2024,
  author = {Di Molfetta, Sergio and Di Gioia, Ludovico and Caruso, Irene and Cignarelli, Angelo and Green, Suetonia C and Natale, Patrizia and Strippoli, Giovanni F M and Sorice, Gian Pio and Perrini, Sebastio and Natalicchio, Annalisa and Laviola, Luigi and Giorgino, Francesco},
  title = {Efficacy and Safety of Different Hybrid Closed Loop Systems for Automated Insulin Delivery in People With Type 1 Diabetes: A Systematic Review and Network Meta‐Analysis},
  journal = {Diabetes/Metabolism Research and Reviews},
  year = {2024},
  volume = {40},
  number = {6},
  doi = {10.1002/dmrr.3842}
}
Kostenlos starten →